
Renal Cell Carcinoma
Latest News

Latest Videos

CME Content
More News

During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.

A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.

During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.

Regina Barragan-Carrillo, MD, discusses an abstract which evaluated the association between thymectomy and incidence of renal cell carcinoma.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

Immune checkpoint inhibitor-based treatment was equally effective as a frontline treatment for both Black and White patients with metastatic renal cell carcinoma in separate analyses.

Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.

Dr. Motzer shares his viewpoint on quality-of-life preservation observed with different regimens for nccRCC patients.

Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.

During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.



























